Semaglutide 2.4 mg weekly cut weight by **18%** in post-bariatric patients with poor loss.
Background
A suboptimal clinical response following metabolic and bariatric surgery (MBS), defined as less than 20% weight loss from surgery, is a common and significant health concern. This often leads to weight regain and persistent metabolic dysfunction, despite initial surgical intervention. Current strategies for managing this post-surgical weight plateau are limited, leaving a gap for effective pharmacological adjuncts. GLP-1 receptor agonists like semaglutide are being explored due to their established efficacy in weight management and metabolic improvement, offering a potential solution for this challenging patient population.
Study Design
The BARI-STEP trial, a double-blinded, randomized (1:1), placebo-controlled study, recruited 70 adult participants at least 1 year post-gastric bypass or sleeve gastrectomy who had achieved less than 20% weight loss from surgery. Participants were randomized to receive either semaglutide 2.4 mg weekly (n=35) or placebo (n=35) as an adjunct to a lifestyle intervention including a 500-kcal daily energy deficit. The treatment duration was 68 weeks, with the primary outcome being the percentage weight loss from baseline, analyzed on an intention-to-treat basis.
Results
After 68 weeks, participants receiving semaglutide 2.4 mg demonstrated a substantial reduction in body weight. The estimated mean percentage weight loss from baseline was -18.0% (s.d. 9.2) in the semaglutide group (n=34), compared to a slight increase of +0.4% (s.d. 7.0) in the placebo group (n=29).
Key Findings
- Semaglutide 2.4 mg weekly reduced body weight by -18.0% over 68 weeks in post-bariatric patients.
- Placebo group showed a mean weight change of +0.4% over the same period.
- Adjusted mean treatment difference was -19.18% (95% CI -23.4% to -14.8%;
P<0.001) favoring semaglutide. - Adverse events were consistent with semaglutide's known safety profile, with no new concerns for this population.
- Semaglutide improved metabolic parameters and quality of life compared to placebo.
Why It Matters
This study provides compelling evidence that semaglutide 2.4 mg weekly is a safe and effective treatment option for individuals experiencing suboptimal weight loss after bariatric surgery. For peptide users and clinicians, this means a powerful pharmacological tool is available to address weight regain or insufficient initial response, potentially improving long-term outcomes and reducing the need for revision surgeries. The explicit dosing protocol of 2.4 mg weekly offers a clear, actionable strategy for integrating semaglutide into post-bariatric care. This finding expands the utility of GLP-1RAs beyond primary weight management, addressing a critical unmet need in a challenging patient population.
semaglutide
bariatric-surgery
weight-loss
obesity
glp-1-agonist
clinical-trial